Follow-up period | ||||
---|---|---|---|---|
> 3 months – 10 years | > 10 years | |||
Type of event | Unadjusted HR (95% CI) | Adjusted* HR (95% CI) | Unadjusted HR (95% CI) | Adjusted* HR (95% CI) |
Local recurrence ( in situ or invasive) | No. of events: 84 | No. of events: 17 | ||
Luminial A | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) |
Luminal B/HER2- | 1.39 (0.64-3.01) | 1.61 (0.73-3.54) | no events | - |
Luminal B/HER2+ | 1.31 (0.72-2.40) | 1.63 (0.84-3.17) | 0.78 (0.21-2.89) | 1.01 (0.22-4.62) |
HER2+/ER- | 1.21 (0.62-2.34) | 1.77 (0.85-3.68) | 0.27 (0.03-2.14) | 0.58 (0.06-5.89) |
Triple negative | 1.37 (0.57-3.28) | 1.38 (0.56-3.38) | 0.94 (0.12-7.44) | 0.78 (0.09-7.22) |
Unclassified | 0.73 (0.36-1.49) | 0.77 (0.38-1.58) | 0.95 (0.25-3.60) | 1.19 (0.29-4.78) |
Invasive or general recurrence | No. of events: 47 | No. of events: 19 | ||
Luminial A | 1.0 | 1.0 | 1.0 | 1.0 |
Luminal B/HER2- | 2.02 (0.80-5.13) | 2.51 (0.97-6.49) | no events | - |
Luminal B/HER2+ | 1.49 (0.68-3.25) | 1.97 (0.83-4.67) | 0.78 (0.25-2.44) | 0.72 (0.21-2.56) |
HER2+/ER- | 0.71 (0.24-2.12) | 0.98 (0.31-3.17) | no events | - |
Triple negative | 2.24 (0.83-6.06) | 1.99 (0.70-5.63) | 0.82 (0.11-6.35) | 0.63 (0.07-5.48) |
Unclassified | 0.70 (0.26-1.90) | 0.84 (0.31-2.33) | 0.54 (0.12-2.42) | 0.53 (0.12-2.42) |
All events | No. of events: 112 | No. of events: 28 | ||
Luminial A | 1.0 | 1.0 | 1.0 | 1.0 |
Luminal B/HER2- | 1.24 (0.62-2.46) | 1.47 (0.73-2.94) | no events | - |
Luminal B/HER2+ | 1.20 (0.71-2.01) | 1.53 (0.87-2.71) | 0.40 (0.12-1.37) | 0.39 (0.11-1.45) |
HER2+/ER- | 0.92 (0.49-1.70) | 1.28 (0.65-2.52) | 0.17 (0.02-1.25) | 0.20 (0.03-1.58) |
Triple negative | 1.30 (0.61-2.75) | 1.37 (0.64-2.98) | 2.95 (1.07-8.16) | 3.21 (1.05-9.83) |
Unclassified | 0.78 (0.43-1.39) | 0.82 (0.45-1.48) | 0.85 (0.28-2.58) | 1.02 (0.33-3.21) |